In fact, overexpression of the AT1-R activates STAT3 while either the pharmacological blockade of the AT1-R or downregulation of HMGA1, the transcriptional activator of the AGT gene promoter in NSCLC cells, inhibits activation of STAT3 in NSCLC cells. This evidence concerns the gene STAT3 and non-small cell lung carcinoma.